Description
IGF::OT::IGF TO INCORPORATE ADDITIONAL IMMUNOSUPPRESSANT DRUGS
Modification chain · 5 transactions
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2016-10-19+$684,128= $684,128
- Mod P000012017-07-27+$20,000= $704,128
- Mod P000022018-02-21+$7,977= $712,105
- Mod P000032018-03-08-$154,115= $557,990
- Mod P000042018-03-09-$28,076= $529,914
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2016-10-19 | +$684,128 | $684,128 | IGF::OT::IGF TO INCORPORATE ADDITIONAL IMMUNOSUPPRESSANT DRUGS |
| Mod P00001· CHANGE ORDER | 2017-07-27 | +$20,000 | $704,128 | IGF::OT::IGF TO INCORPORATE ADDITIONAL IMMUNOSUPPRESSANT DRUGS |
| Mod P00002· CLOSE OUT | 2018-02-21 | +$7,977 | $712,105 | IGF::OT::IGF TO INCORPORATE ADDITIONAL IMMUNOSUPPRESSANT DRUGS |
| Mod P00003· FUNDING ONLY ACTION | 2018-03-08 | −$154,115 | $557,990 | IGF::OT::IGF TO INCORPORATE ADDITIONAL IMMUNOSUPPRESSANT DRUGS |
| Mod P00004· FUNDING ONLY ACTION | 2018-03-09 | −$28,076 | $529,914 | IGF::OT::IGF TO INCORPORATE ADDITIONAL IMMUNOSUPPRESSANT DRUGS |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI NH3LDK8CFAK7)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36C24426N1004 | 244-NETWORK CONTRACT OFFICE 4 (36C244) · 6550 · IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS | $187,594 | FY2026 |
| 36C24426N1005 | 244-NETWORK CONTRACT OFFICE 4 (36C244) · 6550 · IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS | $395,322 | FY2026 |
| 36C24426N1001 | 244-NETWORK CONTRACT OFFICE 4 (36C244) · 6550 · IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS | $431,969 | FY2026 |
| 36C24426N1003 | 244-NETWORK CONTRACT OFFICE 4 (36C244) · 6550 · IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS | $267,954 | FY2026 |
| 36C24426N1002 | 244-NETWORK CONTRACT OFFICE 4 (36C244) · 6550 · IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS | $607,544 | FY2026 |
| 36C24426N1006 | 244-NETWORK CONTRACT OFFICE 4 (36C244) · 6550 · IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS | $783,641 | FY2026 |
Other recipients under W052 from 242-NETWORK CONTRACT OFFICE 02 (36C242) (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| 36C24218P3441 | RSOTOGO | 242-NETWORK CONTRACT OFFICE 02 (36C242) | $330,850 | FY2018 |
| 36C24218P2113 | FUJIFILM HEALTHCARE AMERICAS CORP | 242-NETWORK CONTRACT OFFICE 02 (36C242) | $5,200 | FY2018 |
| 36C24218P0689 | FUJIFILM HEALTHCARE AMERICAS CORP | 242-NETWORK CONTRACT OFFICE 02 (36C242) | $10,400 | FY2018 |
| VA24217P1071 | HITACHI ALOKA MEDICAL AMERICA, INC. | 242-NETWORK CONTRACT OFFICE 02 (36C242) | $5,200 | FY2017 |
| VA24217P0907 | HITACHI ALOKA MEDICAL AMERICA, INC. | 242-NETWORK CONTRACT OFFICE 02 (36C242) | $5,200 | FY2017 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_VA24217J0221_3600_VA24312A0047_3600 · retrieved 2026-09-26.